Daiichi Sankyo submits edoxaban to European regulators


Daiichi Sankyo (DSKYF +1.2%) submits a MAA for edoxaban.

The company wants the direct factor Xa-inhibitor approved for stroke and SEE prevention in NVAF patients, for the treatment of DVT or PE, and for the prevention of VTE.

For more on edoxaban, see here.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs